Question 1

What does peer-reviewed research say about these claims?

Accepted Answer

Bro translation: The claims in this clip regarding biotin interference with thyroid assays and the synergistic role of Vitamin K2 in calcium deposition are supported by mainstream medical literature and do not represent a significant evidence gap. The 'normal is not optimal' rhetoric is a common wellness industry trope rather than a medically unsupported claim, though it is often used to justify non-standard testing.

Question 2

Are Jaban M Moore's credentials legitimate?

Accepted Answer

Jaban Moore presents as a chiropractor, a real state-regulated credential with a narrower musculoskeletal and nervous-system scope. The site nevertheless markets broad disease-cause assessment and systemic detoxification concepts, creating credential inflation through specialty overreach. Stated credentials: none detected. Likely credentials: Chiropractor (DC), DC. Credential inflation detected, a white coat is not the same as an MD/DO license.

Question 3

Is Dr Jaban M Moore a real medical doctor?

Accepted Answer

Jaban M Moore is not identified as an MD/DO physician in reviewed credentials or public registry data. Likely credential: Unknown (requires main site verification).

Question 4

Does Jaban M Moore use Sales Funnel Motive?

Accepted Answer

The host uses a vague medical complaint ('feel depleted' despite 'normal labs') to invite public engagement, which is a classic funnel tactic to identify potential patients for private consultation or to drive traffic to a booking link not visible in this short clip. Likely motive: Lead generation for paid consultations or supplement sales

Question 5

Does Jaban M Moore use False Authority?

Accepted Answer

The host leverages the common wellness industry trope that 'normal' lab ranges are insufficient, implying that mainstream medicine is failing the patient. This creates anxiety about standard care to justify non-standard testing or supplement protocols. Likely motive: Creating demand for alternative testing or 'optimization' supplements

Question 6

Is the claim "Vitamin K2 works alongside vitamin D to steer calcium into bone rather than arteries, w…" supported by medical literature?

Accepted Answer

Vitamin K2 is a cofactor for γ‑carboxylation of osteocalcin and matrix Gla protein, which are involved in directing calcium into bone and inhibiting vascular calcification according to multiple reviews and mechanistic discussions in the academic literature (inferred from the 2017 and later reviews/meta-analyses identified in the search). Several randomized trials and reviews report that vitamin K2 supplementation, often alongside vitamin D and calcium, can modestly improve bone mineral density and fracture-related outcomes in postmenopausal women and other groups, consistent with a role in skeletal calcium handling, though effect sizes are generally small and not always specific to K2 alone. A recent narrative and mechanistic review on vitamins D and K describes them as having potentially synergistic roles in bone metabolism and calcium homeostasis, with vitamin D increasing calcium availability and vitamin K2 activating proteins that bind and utilize calcium in bone (carboxylated osteocalcin), which conceptually supports the idea that they can work together to promote bone mineralization. There are RCTs and meta-analyses showing vitamin K supplementation can lower biochemical markers of vascular calcification (e.g., dephosphorylated-uncarboxylated MGP) and in some pooled analyses slightly slow the progression of coronary artery calcification scores, suggesting a possible protective effect on arteries, although the results are modest and population-specific. Overall, high‑quality evidence supports that vitamin K (especially K2) has beneficial effects on bone health and may favourably influence vascular calcification markers, and that co-supplementation with vitamin D is biologically plausible and supported by some clinical data, but this is far from definitive for “steering calcium” in a strong causal sense. Systematic reviews of vitamin K supplementation and vascular calcification in high‑risk populations such as chronic kidney disease patients conclude that, despite improvements in biochemical markers, there is not yet solid evidence from randomized controlled trials that vitamin K (including K2) meaningfully reduces radiologically measured vascular calcification or hard cardiovascular outcomes; calcification scores often do not change significantly even when surrogate markers improve. Several RCTs in dialysis and CKD cohorts show that vitamin K2 lowers levels of inactive MGP but does not significantly alter aortic or coronary calcification progression over typical trial durations, which contradicts a strong claim that K2 reliably keeps calcium out of arteries. Large guidelines in hypertension, parenteral nutrition, neurology, transfusion medicine, and general clinical nutrition (including ASPEN and ESPEN) do not recommend routine vitamin K2 co‑supplementation with vitamin D specifically to prevent arterial calcification or to “steer calcium” from arteries to bone, which indicates that this mechanism is not accepted as a proven clinical effect in guideline-level evidence. Major evidence syntheses on vitamin K and osteoporosis note that intervention trials are heterogeneous and often inconclusive, with benefits on bone loss and fractures modest and not always reproducible, especially in adults already replete in calcium and vitamin D; this weakens the claim that simply adding K2 to vitamin D fundamentally changes calcium partitioning between bone and arteries. Importantly, there is no high‑quality evidence showing that vitamin D “loading” without K2 systematically increases arterial calcification or backfires clinically, so the warning that supplementing vitamin D alone is harmful in this way overstates the current evidence. The mainstream medical and scientific view is that vitamin D is essential for calcium absorption and bone health and that vitamin K (including K2) plays important roles in activating proteins involved in bone mineralization and inhibition of vascular calcification, but the clinical impact of supplemental vitamin K2, especially in combination with vitamin D, is still under active investigation and not established as a standard of care. Existing RCTs and meta-analyses suggest possible modest benefits of K2 for bone density and fracture risk in some populations, and potential but unproven benefits for slowing vascular calcification in selected high‑risk groups; however, evidence is inconsistent, often limited by small sample sizes, short follow‑up, and reliance on surrogate endpoints rather than major clinical outcomes. Major guidelines in endocrinology, cardiology, and nutrition currently do not recommend routine vitamin K2 co‑supplementation with vitamin D solely to redirect calcium from arteries to bone or to prevent vitamin D‑related vascular harm, reflecting the view that mechanistic plausibility and emerging data are insufficient to justify such broad claims. Standard Literature verdict: mixed.

Question 7

Is the claim "Biotin can distort thyroid and hormone results, so a panel can look abnormal when the r…" supported by medical literature?

Accepted Answer

Biotin can interfere with biotin-streptavidin based immunoassays and produce falsely high or low results depending on assay design, including thyroid tests such as TSH, free T4, free T3, and thyroglobulin. The effect is clinically important enough that reviews and case series recommend considering biotin use when thyroid results are discordant with symptoms and withholding biotin before testing. A daily dose of 10 mg has been shown to interfere with specific thyroid assays, and a 10,000 mcg daily dose has caused biochemical hyperthyroidism that normalized after stopping biotin. Biotin is commonly present in hair, skin, and nail supplements, so a “hair supplement” can indeed be the culprit behind abnormal thyroid panels in some patients. The claim is too broad if interpreted to mean biotin commonly distorts all thyroid or hormone tests, or that any abnormal panel is likely due to biotin. Interference is assay-specific, dose-dependent, and platform-dependent; some assays show no effect even when others are affected. Evidence is strongest for thyroid immunoassays and some other streptavidin-biotin based tests, but not for every thyroid or hormone measurement method, and mass spectrometry or non-biotin assay platforms may be unaffected. The user-provided index papers are about hypertension, nutrition, headache, blood transfusion, and colchicine in pericarditis, and do not directly support or refute the biotin claim. Evidence from the broader literature is largely case reports, lab-method studies, and guidance statements rather than large outcome-focused randomized trials. Mainstream medical and laboratory medicine guidance is that biotin supplements can cause clinically meaningful interference in some immunoassays, especially thyroid tests, and clinicians should ask about supplement use when results do not fit the clinical picture. The accepted interpretation is not that biotin always causes abnormal results, but that it is a well-recognized, assay-dependent confounder that can mimic thyroid disease and should be withheld before testing when relevant. Literature verdict: partially supported.

Question 8

Is the claim "With vitamins, more is not the same as better, and normal is not the same as optimal." supported by medical literature?

Accepted Answer

High‑quality evidence and guidelines consistently emphasize that vitamin intake has an upper safe limit, and more is not necessarily better. Risk‑assessment frameworks such as tolerable upper intake levels (ULs) for vitamins and minerals are explicitly designed to identify the highest daily intake likely to pose no risk, highlighting that intakes beyond this can increase adverse effects rather than benefits.[7][16][21] Systematic reviews and meta‑analyses of antioxidant vitamins show that high‑dose supplementation (vitamin A, beta‑carotene, and vitamin E) is associated with increased all‑cause mortality, not improved outcomes, which supports the idea that “more” can be harmful.[9][10][11] Multivitamin–multimineral meta‑analyses find no mortality benefit from routine supplementation in generally well‑nourished populations, indicating that taking more than needed does not confer extra survival advantage.[15] Clinical and survey data on vitamin D show that inappropriate high‑dose supplementation leads to very high serum 25(OH)D levels and hypercalcemia in a subset of patients, reinforcing that exceeding guideline‑based dosing can cause toxicity.[4] Major nutrition guidelines (e.g., ASPEN, ESPEN) and UL frameworks are based on defining required intake, avoiding deficiency, and preventing toxicity, not pushing intake far above normal ranges, which implicitly supports “more is not better.”[1][2][3][7][16][21] Several systematic reviews on vitamin D and other vitamins describe U‑ or J‑shaped relationships between serum levels and outcomes, with worse outcomes at both very low and very high levels, suggesting an optimal range rather than a simple “higher is better” pattern (normal vs optimal distinction). A partial counterpoint to the blanket claim comes from meta‑analyses showing modest benefits of vitamin D supplementation on total mortality in some adult populations, particularly when correcting deficiency, which suggests that increasing vitamin levels from low or borderline “normal” toward higher within‑range levels can improve outcomes under specific conditions.[18][20] Some disease‑specific reviews (e.g., vitamin D in chronic rhinosinusitis or in dental implant osseointegration) report clinical benefits from supplementation and recommend ensuring serum levels are at least normal to support optimal outcomes, which can be interpreted as “normal is not always optimal” but also shows that more (up to guideline‑consistent levels) can be better when starting from deficiency or low normal, complicating a simple “more is not better” rule.[1][6] Observational and interventional data in cancer and other chronic diseases sometimes suggest that higher 25(OH)D within a physiological range is associated with better prognosis or treatment response; however, this benefit tends to plateau and may reverse at very high levels, so the evidence does not support unlimited “more,” but it does contradict a strict view that increasing vitamins above a low baseline is never beneficial.[2][14] There is limited high‑quality evidence establishing precise “optimal” levels above standard normal ranges for most vitamins; many proposed optimal targets are based on observational associations and surrogate endpoints, so claims that normal is broadly suboptimal are not strongly substantiated across all micronutrients. The available guideline papers in the index set focus on deficiency, adequacy, and toxicity rather than defining a distinct supra‑normal optimal zone.[2][3][7][16][21] Mainstream medical and nutritional guidance holds that vitamins are essential in defined amounts, that deficiency should be corrected, and that routine high‑dose supplementation above recommended intakes is generally unnecessary and may be harmful. Regulatory and expert bodies use recommended dietary allowances (RDAs) or equivalent and tolerable upper intake levels (ULs) to frame intakes, explicitly recognizing that there is a range of intake between deficiency and toxicity, and that crossing the upper range increases risk without proven added benefit for most people.[7][16][19][21] In practice, clinicians aim for serum vitamin levels within established normal or physiological ranges and avoid both deficiency and excess; in some conditions, they may target the upper part of the normal range (e.g., for vitamin D in certain disease states), but they do not endorse indiscriminate megadoses beyond ULs. High‑dose antioxidant supplementation (vitamins A, E, beta‑carotene) is generally discouraged because of meta‑analytic evidence of increased mortality.[9][10][11][13][15] The mainstream view therefore agrees strongly that “more is not better” once adequate status is reached and ULs are approached or exceeded, and it cautiously Literature verdict: mixed.

Jaban Moore alias The Optimal Vitamin Oracle

Score breakdown

Key findings

Claims & evidence

Manipulation

Commerce & grift map

Credentials & scope

Validated associated properties

Analyzed

Funnel routes (third-party)

Tip the jar

Fight disinformation

Log a new mention

Reply snippets

Recent mentions (this doc)

Nudge the Doc Bro

Pick a contact address

What gets sent

Know someone who can help?

Who should we nudge?

What gets sent

Whambulance

Public challenge log

File a challenge

Citations